Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02240355 · ClinicalTrials.gov registry record · Phase 1
A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02240355 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 9 participants.
The verdict
NCT02240355, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This multicenter, randomized, double-blind, 12-week, placebo-controlled multiple dose study will investigate the safety and tolerability of RO6885247 in adult and pediatric patients with spinal muscular atrophy (SMA).
Interventions
- DRUG placebo
- DRUG RO6885247
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02240355
The ClinicalTrials.gov registry entry for NCT02240355 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02240355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02240355 about?
NCT02240355 is a clinical study titled "A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)". This multicenter, randomized, double-blind, 12-week, placebo-controlled multiple dose study will investigate the safety and tolerability of RO6885247 in adult and pediatric patients with spinal muscular atrophy (SMA).
What is the current status of trial NCT02240355?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2014-11. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02240355?
The interventions under investigation include: placebo (DRUG), RO6885247 (DRUG).
Who is sponsoring clinical trial NCT02240355?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.